3 ms·
It’s disingenuous to call it “the Moderna mRNA vaccine” when it was more accurately “one early Moderna mRNA vaccine candidate, which was ruled out for being far
by thehappypm 6y ago
It’s disingenuous to call it “the Moderna mRNA vaccine” when it was more accurately “one early Moderna mRNA vaccine candidate, which was ruled out for being far too high of a dose”.
- zerobits 6y agoThanks for the valid correction. I didn’t mean to be disingenuous. I forgot they rejected that dosage. Overall, the picture does look potentially concerning for the side effects of that vaccine and efficacy is still unclear.
- thehappypm 6y agoWhat makes it concerning? Tylenol is concerning if you take 2.5x the safe dose. Of course the efficacy is unclear — it’s still in trials!
- zerobits 6y agoThere was a pretty high severe systemic adverse rate in the high dose group (20%). Severe local response rate was 5% in the middle dose. [1] I have no idea how this compares to other vaccines, and you can pessimistically extrapolate a bit from this tiny, healthy sample from the high dose (n=15 in middle dose group). I'd imagine some % of people when this scales to millions will have a bad response, and the high dose group might provide some model of the worst cases. [1] https://www.nejm.org/doi/full/10.1056/nejmoa2022483 https://www.nejm.org/doi/full/10.1056/nejmoa2022483
- DrAwdeOccarim 6y agoI think the comparison most are making is to Shingrix. Have a look at Table 2[1]. [1] https://www.nejm.org/doi/pdf/10.1056/NEJMoa1603800 https://www.nejm.org/doi/pdf/10.1056/NEJMoa1603800